



Boston, MA

June 5-8, 2023

ALBERTA @

2023

BIO INTERNATIONAL

www.bioalberta.com

ABOUT

Fast facts

- Population in 2022: 4.6 million
- GDP in 2022: \$339.3 billion

Competitive taxes

- Albertans pay the lowest overall taxes in Canada.
- We have a competitive tax system with low personal and corporate income tax rates, no payroll tax, no provincial sales tax and no health premiums.

A skilled and productive workforce


- Alberta's labour force consists of more than 2.5 million workers aged 15 and up.

Recognized nationally and internationally for our expertise in:

- Artificial Intelligence (AI) and Machine Learning
- Research and Development
- Clinical research
- COVID-19 research


ABOUT

Life Sciences business classification



(SOI) 2023

Life Sciences sector classification



(SOI) 2023

CONTENTS

- | | | | | | |
|----------|--|-----------|---|-----------|--------------------------------|
| 2 | About | 10 | Edmonton Global | 17 | University of Alberta |
| 3 | About | 11 | Entos | 18 | University of Calgary |
| 5 | Alberta Innovates | 12 | GlycoNet | 19 | University Hospital Foundation |
| 6 | Alberta Real World Evidence Consortium | 13 | NAIT Centre for Advanced Medical Simulation | 20 | Sinoveda |
| 7 | Applied Pharmaceutical Innovation | 14 | Northern RNA | 21 | Syantra |
| 8 | BioAlberta | 15 | Pacylex | 22 | Xortx |
| 9 | Calgary Economic Development | 16 | Providence Therapeutics | 23 | 48Hour Discovery |



Alberta Innovates

Alberta Innovates is the province's largest and Canada's first provincial research and innovation agency. For a century we have worked closely with researchers, companies and entrepreneurs – trailblazers who built industries and strengthened communities. Today we are pivoting to the next frontier of opportunity in Alberta and worldwide by driving emerging technologies across sectors. We are a provincial corporation delivering seed funding, business advice, applied research and technical services, and avenues for partnership and collaboration.

BUSINESS OBJECTIVES

Alberta Innovates supports innovators and solution-finders across the province with our programs, our funding and our talented staff. The entrepreneurs and ideas we help to advance will solve problems and build new opportunities and capacity in the innovation economy – from digital health to smart agriculture, from clean resource technologies to artificial intelligence and advanced manufacturing – all of which leverage Alberta's existing advantages and strengths.

CONTACT

www.albertainnovates.ca

www.innotechalberta.ca



Alberta Real World Evidence Consortium

The province of Alberta stands out as a global leader in real-world health system data, housing one of Canada's largest, most mature, and comprehensive repositories. This remarkable resource serves as the foundation for the Alberta Real World Evidence Consortium, a highly experienced cross-functional provincial research team from the Universities of Alberta and Calgary, along with the Institute of Health Economics. Leveraging this unique asset, the Consortium conducts timely health-focused research using real-world data, engaging funding partners, decision-makers, and knowledge users. Upholding rigorous academic standards, the Consortium ensures the integrity of results.

The Consortium initiates the collaborative research process by considering the interests of our funding partners, and aligning these with our deep understanding of the evidence required to support health care and drug policy decision-making. By doing so, we identify the right research questions and generate meaningful evidence from a trusted source that can be used for informed decision-making.

BUSINESS OBJECTIVES

The Alberta Real World Evidence Consortium provides businesses in the health care sector the opportunity to support collaborative real-world data-driven research that generates meaningful evidence from a trusted source, providing invaluable insights that contribute to advancing health outcomes and supporting the shaping of effective policies and decisions.

CONTACT

Karen Martins, PhD. Associate Director, Research and Strategy

Email: rweconso@ualberta.ca, martinuk@ualberta.ca

www.albertarwe.ca



Applied Pharmaceutical Innovation

API is a not-for-profit organization with an expert interdisciplinary team that works with a network of collaborating organizations. As a whole, we provide the expertise, services, and infrastructure of a pharmaceutical company. We help innovators launch their ideas into the real world, connect industry to the services they need for commercial success, and accelerate all aspects of the drug development process.

BUSINESS OBJECTIVES

- Provide industry with opportunities to access world-class expertise and services.
- Support researchers and startups to create a viable path forward.
- Train and empower post-doctoral fellows and students.

CONTACT

www.appliedpharma.ca



BioAlberta

BioAlberta is a private, not-for-profit industry association representing the growing life sciences sector in the province. Our vision is to build a thriving and globally competitive life sciences industry that fuels key sectors of Alberta's economy. The organization serves as a central voice and organizing hub and champion for the industry, providing leadership through focused activities that promote and enable sector development in Alberta. BioAlberta activities are focused in four key strategic areas:

- Advocacy
- Industry Development
- Networking
- Promotion & Marketing

BUSINESS OBJECTIVES

Primary goal is to assist companies with a successful BIO event, including obtaining meaningful meetings and networking. Secondary to this, BioAlberta is looking to connect with potential companies looking to invest in Alberta, mentors and accelerator programs.

CONTACT

Robb Stoddard, President and CEO
robb@bioalberta.com

+1-587- 597-7622

www.bioalberta.com

Calgary Economic Development

Calgary Economic Development is a not-for-profit corporation funded by the City of Calgary, community partners, other orders of government and the private sector. We work with business, government and community partners to position Calgary as the location of choice for the purpose of attracting business attraction & investment, fostering trade and developing Calgary's workforce.

BUSINESS OBJECTIVES

Interested in companies who have a desire to learn more about investment opportunities in Calgary or have questions about doing business, expanding or relocating to Alberta. Life sciences

CONTACT

Marlise Stewart, Business Development
mstewart@calgaryeconomicdevelopment.com

www.calgaryeconomicdevelopment.com



Edmonton Global

The purpose of Edmonton Global is to radically transform and grow the economy of the Edmonton Metropolitan Region.

Our work promotes the region globally and we're focused on attracting and retaining business investment and trade right here.

We are the first ever regional economic development corporation in the region, working to create local, regional, provincial, national, and global partnerships. We collaborate with all levels of government and economic development agencies including our 14 municipalities, Invest Alberta, Alberta's Industrial Heartland Association, the Edmonton International Airport, Edmonton Health City, the Alberta Machine Intelligence Institute, and Invest in Canada.

BUSINESS OBJECTIVES

Edmonton Global's vision is to make the Edmonton Metropolitan Region the choice location for global investment. To attract investment and quality jobs to the region, our strategy is to strengthen and support growth, innovation, and competitiveness — all in collaboration with the region's 14 municipalities.

As a foreign direct investment (FDI) and international business development company, we work as an ally to attract investment to, and promote trade from, Canada and our region. We're ready to connect with you and support your work.

CONTACT

www.edmontonglobal.ca



Entos Pharmaceuticals, Inc.

A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. With our partners, such as Eli Lilly and BioMarin, we are developing next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of mRNA or DNA into target cells through direct fusion.

BUSINESS OBJECTIVES

Network with investors, industry, and Canadian government officials to promote Entos and its Fusogenix PLV platform and increase funding for the development and biomanufacturing of Canadian-made genetic medicines and vaccines.

CONTACT

John Lewis, Ph.D. CEO, Entos Pharmaceuticals
info@entospharma.com

www.entospharma.com



GlycoNet

GlycoNet

The Canadian Glycomics Network (GlycoNet) is a research-led, science-backed national leader in the field of glycomics. Our mission is to accelerate enabling technologies and deliver health products in the form of therapeutics, vaccines, and diagnostics.

We have a network of 170+ researchers at institutes from across Canada. Our current funded glycomics projects are in the areas of:

- Oncology (e.g. breast, pancreatic, prostate, pan-cancer)
- Diabetes (e.g. Type I, Type II)
- Other chronic diseases (e.g. inflammatory bowel disease, heart disease, stroke, multiple sclerosis)
- Rare genetic diseases (e.g. San Filippo, Tay-Sachs, muscular dystrophy,
- Neurodegenerative diseases (e.g. Alzheimer's, Parkinson's, Huntington's)
- Antimicrobials and infectious diseases (e.g. viral, fungal, bacterial)
- Enabling technologies (e.g. drug discovery, glycoengineering, cell therapy)

BUSINESS OBJECTIVES

In support of strategic partnerships and venture creation, GlycoNet is targeting additional funding to translational stage research as well as the protection of intellectual property.

GlycoNet's goal is to establish a successful innovation hub in glycomics research and translation through securing partnerships and funding opportunities, commercialization of technologies and creation of spin-off companies.

We seek partners to accelerate and power our portfolio of translational research via licensing or collaborations

- Seek investors that can fund discovery/preclinical technologies
- Seek early-stage investors for new company creation

CONTACT

www.canadianglycomics.ca



CENTRE FOR ADVANCED MEDICAL SIMULATION

NAIT Centre for Advanced Medical Simulation

The Centre for Advanced Medical Simulation (CAMS) enhances patient safety, provides real-world clinical simulation training for students and educators, and fills the gap from concept to validation in the current health innovation space by providing access to safe, realistic and available environments to test products, services, and prototypes.

BUSINESS OBJECTIVES

- Transform patient care through medical simulation, education, technology, and applied research.
- Support hands-on, immersive simulation in a flexible, interprofessional setting to ensure the highest standard of quality, interactive education.
- Enhance patient safety for students and industry professionals by providing adaptable, real-world scenarios.

CONTACT

www.nait.ca/cams



Northern RNA

Northern RNA is a Canadian contract development and manufacturing organization (CDMO) specializing in the production of nucleic acid products that support life-enabling work. We support our clients by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field.

Our goal at Northern RNA is to be a world leading, customer-focused, end-to-end supplier of nucleic acid products such as mRNA and DNA. We strive towards this goal daily by developing and deploying our state-of-the-art bioprocessing and chemical process technologies, using proprietary manufacturing and analytical approaches, employing a highly-skilled workforce and partnering with an excellent and extensive network of relationships and collaborations.

BUSINESS OBJECTIVES

- Provide products, services and support for nucleic acid vaccine and therapeutic programs using our state-of-the-art equipment and proprietary processes.
- Provide construct design support, development services, best-in-class raw material, GMP final products, and regulatory support for our clients at every stage of the pipeline.
- Utilize our world class pan-disciplinary talent across chemistry, biology, biochemistry, biophysics, supply chain, quality management, business development and more to support our clients.
- Provide the trust and confidence in product quality and integrity along with supply security to our clients globally.

CONTACT

Tim Morgan, Director of Business Development
tmorgan@northernrna.com

Jared Davis, President and CTO
jdavis@northernrna.com



Pacylex

Pacylex is developing PCLX-001, a first-in-class, once daily, oral cancer therapy with a novel, broad, mechanism of action. PCLX-001 attacks the membrane-associated proteins at the root of cancer signaling in leukemia and lymphoma. By interrupting cancer signaling before it spreads to redundant pathways, PCLX-001 offers a potent alternative to classic chemotherapies and immunotherapies to kill cancer cells. In an ongoing Phase 1 clinical trial, PCLX-001 has excellent bioavailability, half-life, safety profile, and drug exposure consistent with advancing the program to Phase 2 clinical studies. Pacylex is seeking Series B investors to support two Phase 2 programs in leukemia (AML) and lymphoma (DLBCL) that can lead to registration filings by 2025, and an expansion study in solid tumor patients.

Our diagnostic technology identifies those patients who will benefit from our drug, sparing many patients needless treatment. We are able to do this through our discovery that a subset of patients across many cancer types have lost one of the two proteins required for myristoylation, N-myristoyl transferase 2 (NMT2). This protein loss presents a therapeutic opportunity for our drug candidate, PCLX-

BUSINESS OBJECTIVES

Despite major advances in cancer care, many patients don't survive long after their diagnosis. Fewer than one third of patients diagnosed with lung cancer or acute myeloid leukemia survive for 5 years. Our lead cancer drug eliminates leukemia and lymphoma tumors and inhibits lung and breast cancer tumors in many animal models including with drug resistant patient tumor tissue. We are working now to bring this new medicine to human clinical studies.

CONTACT

www.pacylex.com



Providence Therapeutics

Providence Therapeutics is a private Canadian biotechnology company that specializes in messenger RNA (mRNA) vaccine therapies.

We hold deep expertise in the science of mRNA with operations located in Calgary, Alberta and Toronto, Ontario. The beginnings of Providence Therapeutics started with our undivided focus on oncology research and personalized cancer therapies. However, given the global COVID-19 crisis, we have pivoted from our original mission, devoting our energy, knowledge, and resources to creating a mRNA COVID-19 vaccine, which is currently under Phase 2 Human Clinical Trial.

BUSINESS OBJECTIVES

Providence not only aims to be part of the critical global mRNA COVID vaccine supply pool, but we also look to apply our mRNA platform technology towards various vaccine developments by establishing key collaborations with industry players in the various fields of cancers, therapies and infectious diseases. We extend our invitation to Biotech Industry players, the scientific community, and Academia that wish to reach out to us to discuss viable potential projects that our mRNA platform could play a vital role in.

CONTACT

www.providencetherapeutics.com



UNIVERSITY OF ALBERTA

University of Alberta

The University of Alberta in Edmonton is one of the top teaching and research universities in Canada, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering and health sciences.

BUSINESS OBJECTIVES

Within a vibrant and supportive learning environment, the University of Alberta discovers, disseminates and applies new knowledge through teaching and learning, research and creative activity, community involvement and partnerships. The U of A gives a national and international voice to innovation in our province, taking a lead role in placing Canada at the global forefront.

We inspire the human spirit through outstanding achievements in learning, discovery and citizenship in a creative community, building one of the world's great universities for the public good.

CONTACT

www.ualberta.ca



**UNIVERSITY OF
CALGARY**



**International
Microbiome
Centre**

[University of Calgary](#)

UCalgary is Canada's entrepreneurial university, located in Canada's most enterprising city. It is a top research university and one of the highest-ranked universities of its age. Founded in 1966, its 35,000 students experience an innovative learning environment, made rich by research, hands-on experiences and entrepreneurial thinking. It is Canada's leader in the creation of start-ups. Start something today at the University of Calgary.

BUSINESS OBJECTIVES

Our purpose as a university is to contribute to the body of world knowledge while engaging our students in learning guided by processes of discovery, creativity, and innovation. Our research promotes cultural understanding and social justice, improves quality of life, and helps to secure a prosperous and sustainable future.

We're committed to sharing new knowledge and discoveries generously, and our scholars are working to address society's challenges proactively and making a positive impact in the world around us.

CONTACT

www.research.ucalgary.ca



**University
Hospital
Foundation**

**In support of:
University of Alberta Hospital
Mazankowski Alberta Heart Institute
Kaye Edmonton Clinic**

University Hospital Foundation

The University Hospital Foundation was created in 1962 by an act in the Alberta legislature. In the decades since, we have evolved into one of the most successful hospital fundraising organizations in Canada. We raise funds to advance patient care and innovation at the University of Alberta Hospital, the Mazankowski Alberta Heart Institute and the Kaye Edmonton Clinic.

BUSINESS OBJECTIVES

We are driven to find bold solutions, inspire new ideas, and ignite new discoveries by bringing the right people together and giving them the resources they need to achieve the impossible.

- Our hospitals provide patients with the latest in diagnostic imaging and treatment
- We support breakthrough research that brings discoveries to the bedside

CONTACT

www.givetouhf.ca

SINOVEDA

Sinoveda

Sinoveda Canada Inc. believes you deserve to wake up each morning feeling energetic, pain-free, and confident exactly as you are. We believe you have the power to bounce back from health challenges, and come out the other side radiating anew.

In 2006, SinoVeda began with a simple premise: Healing should be a science. Since then, we've spent the past 15 years researching, developing, and manufacturing clinically proven and natural pharmaceuticals. Our formulas are designed to help you feel radiant from the inside, out.

BUSINESS OBJECTIVES

Sinoveda Canada Inc. adopts an innovative approach to drug discovery by starting with herbs that have a historical record of efficacy. This means that the company focuses on plant-based medicine with a proven track record in traditional medicinal practices. By combining this knowledge of historically effective herbs with their patented pharmaceutical platform technology (PPT), AI, and machine learning, Sinoveda aims to identify and develop novel combination therapies with high efficacy and safety profiles. This unique approach integrates traditional wisdom with cutting-edge technology to advance the drug discovery process and deliver promising new treatments.

CONTACT

www.sinoveda.com



Syantra

Syantra Inc. is a privately held, precision healthcare company that's changing the way diseases are detected and treated.

The company's flagship product, Syantra DX | Breast Cancer, is a screening blood test for the detection of breast cancer. It measures a panel of gene expression biomarkers from whole blood and then uses a software package, developed with machine learning, to interpret data and provide a result of positive or negative.

Syantra DX | Breast Cancer represents an early entrant into the emerging molecular diagnostic sector.

BUSINESS OBJECTIVES

Clinical studies for Syantra DX | Breast Cancer are ongoing through Identify Breast Cancer (IDBC) sites in Canada, the UK and South Korea. US site studies are not currently recruiting.

Syantra Inc. is also working on therapeutics (Syantra RX), utilizing a platform in biomarker and drug discovery that is patented/registered in multiple countries.

CONTACT

www.syantra.com



Xortx

XORTX Therapeutics, Inc. is a drug based biotechnology company primarily focused on orphan disease indications which have aberrant purine metabolism and frequently high serum uric acid imbalance. Our focus on developing kidney therapies also includes therapeutics programs for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections such as SARS-CoV-2.

We possess patents and patent applications that may include U.S. and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.

BUSINESS OBJECTIVES

Technology development is an integral part of our corporate strategy. XORTX Therapeutics is working with a number of development and technological partners with proven competence in manufacturing, non-clinical and clinical program development. Importantly, contract research organizations with experience in clinical and regulatory development as well as an orphan drug focus. Our common goal is to bring novel therapies to market to address the needs of both patients and physicians.

CONTACT

www.xortx.com



48Hour Discovery

Develop. Discover. Decipher.

48 Hour Discovery

Founded in 2017, 48Hour Discovery (48HD) is a revenue stage university of Alberta spin-off headquartered in Edmonton, Alberta. 48HD combines genetically encoded macrocycle libraries, based on unique chemical scaffolds and proprietary algorithms to screen billion-scale libraries of peptide sequences for early-stage drug candidates. The integrated approach to molecular discovery generates drug discovery leads at a fraction of the cost and time when compared to current molecular screening enterprises.

Objective: 48HD seeks collaboration with pharmaceutical companies interested in the use of the 48HD platform for generating new drug leads.

BUSINESS OBJECTIVES

48HD seeks collaboration with pharmaceutical companies interested in the use of the 48HD platform for generating new drug leads.

CONTACT

Martin Truksa, PhD, MBA Vice President, R&D
mtruksa@48hourdiscovery.com

